SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

RBC Capital Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces Price Target of $35

RBC Capital initiates coverage on Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Outperform rating and announces Price Target of $35.

Benzinga · 05/13/2020 09:09

RBC Capital initiates coverage on Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Outperform rating and announces Price Target of $35.